No detrimental effect of a positive family history on postoperative upgrading and upstaging in men with low risk and favourable intermediate-risk prostate cancer: implications for active surveillance

Kathleen Herkommer1 · Nikola Maier1 · Donna P. Ankerst2 · Stefan Schiele1 · Jürgen E. Gschwend1 · Valentin H. Meissner1

Abstract
Purpose To assess whether a first-degree family history or a fatal family history of prostate cancer (PCa) are associated with postoperative upgrading and upstaging among men with low risk and favourable intermediate-risk (FIR) PCa and to provide guidance on clinical decision making for active surveillance (AS) in this patient population.
Methods Participants in the German Familial Prostate Cancer database diagnosed from 1994 to 2019 with (1) low risk (clinical T1c–T2a, biopsy Gleason Grade Group (GGG) 1, PSA < 10 ng/ml), (2) Gleason 6 FIR (clinical T1c–T2a, GGG 1, PSA 10–20 ng/ml), and (3) Gleason 3 + 4 FIR (clinical T1c–T2a, GGG 2, PSA < 10 ng/ml) PCa who were subsequently treated with radical prostatectomy (RP) were analysed for upgrading, defined as postoperative GGG 3 tumour or upstaging, defined as pT3–pT4 or pN1 disease at RP. Logistic regression analysis was used to assess whether PCa family history was associated with postoperative upgrading or upstaging.
Results Among 4091 men who underwent RP, mean age at surgery was 64.4 (SD 6.7) years, 24.7% reported a family history, and 3.4% a fatal family history. Neither family history nor fatal family history were associated with upgrading or upstaging at low risk, Gleason 6 FIR, and Gleason 3 + 4 FIR PCa patients.
Conclusion Results from the current study indicated no detrimental effect of family history on postoperative upgrading or upstaging. Therefore, a positive family history or fatal family history of PCa in FIR PCa patients should not be a reason to refrain from AS in men otherwise suitable.

Keywords Active surveillance · Family history · Fatal family history · Favourable intermediate-risk prostate cancer · Upgrading · Upstaging

Introduction
Active surveillance (AS) has emerged as a standard initial management option for low-risk prostate cancer (PCa) to reduce overtreatment and treatment-associated morbidity. Recently, National Comprehensive Cancer Network guidelines recommended AS as an option for men with favourable intermediate-risk (FIR) PCa [1]. However, whether AS can be safely extended to FIR PCa patients remains a matter of debate [2–4]. Risk stratifications prior to treatment decisions are primarily based on biopsy Gleason Grade Group (GGG), clinical stage, and prostate-specific antigen (PSA) levels. Significant sampling error and morbidity associated with prostate biopsy complicates differentiation between aggressive and indolent disease so that post-radical prostatectomy (RP) upgrading and upstaging is common [5–7]. Recently,
multi-parametric magnetic resonance imaging (mpMRI) showed improvements in risk stratification of men on AS and was recommended for enhancing enrolment and monitoring decision [8–10].

A series of prior studies have suggested older age and African American race to be associated with higher rates of postoperative upgrading and upstaging [6, 11, 12]. Whether a first-degree family history of PCa correlates with higher rates of upgrading and upstaging has been less well-studied, with only one study reporting no association among low-risk familial PCa patients [13]. Whether men with FIR PCa and family history or fatal family history are at particularly high risk of harbouring undetected high-grade or high-stage disease has to date not been investigated. Patients with a familial burden of lethal or advanced PCa might experience higher levels of anxiety and may, therefore, feel uncomfortable with AS.

The aim of this study was to assess whether family history or fatal family history is associated with rates of postoperative upgrading and upstaging among men with low risk and FIR PCa to provide guidance on clinical decision making for AS for these patients.

Patients and methods

Database and patient population

The prospective multicentre German Familial Prostate Cancer study has been recruiting and surveying newly diagnosed PCa patients independent of their family history since 1994 [14, 15]. Briefly, patients are referred by attending urologists and cooperating clinics throughout Germany. Patients report sociodemographic data whereas clinicopathological data are verified by a histopathological report or a doctor’s letter. Informed consent is obtained from each patient. The study was approved by the ethical review committee of the Technical University of Munich.

Patients from the study diagnosed between 1994 and 2019 with low risk or FIR PCa and treated with RP were identified. Patients with neoadjuvant or other first-line therapies were excluded. Eligible patients were classified by AUA risk strata [16]. Low-risk PCa was defined as clinical T1c–T2a, biopsy GGG 1, and PSA < 10 ng/ml. FIR PCa was further subclassified into Gleason 6 FIR PCa (clinical T1c–T2a, GGG 1, PSA 10–20 ng/ml) and Gleason 3 + 4 FIR PCa (clinical T1c–T2a, GGG 2, PSA < 10 ng/ml). Gleason score was assigned according to the 2005 International Society of Urological Pathology Consensus Conference on Gleason Grading of Prostatic Carcinoma [17]. Accordingly, newer GGG designations were applied.

Sociodemographic and clinical data included age at surgery, PSA at diagnosis, digital rectal examination (DRE), adjuvant radiotherapy, and adjuvant hormone therapy. Cancer family history included family history of PCa and other cancer, fatal family history (defined as at least one first-degree relative who died of PCa), and secondary cancer of the patient. family history of PCa was stratified into hereditary PCa according to the Johns Hopkins criteria [18], first-degree relatives with PCa, and non-familial first-degree PCa. Pathological data included pathological tumour stage, pathological node stage, surgical margin, and pathological GGG. Data on patients diagnosed before 2002 were adjusted to the UICC TNM classification 2002.

Statistical analysis

Participant characteristics were presented by descriptive statistics. Primary outcomes were upgrading, defined as postoperative GGG 3 tumour in RP and upstaging, defined as pT3–pT4 or pN1 disease at RP. Single logistic regression analysis was employed to determine univariate associations of family history, fatal family history, and all patient risk factors with outcomes. Multiple logistic regression with backward elimination (selection level 5%) was subsequently implemented to identify independent effects from other risk factors. Odds ratios (OR) with 95% confidence intervals (CI) and two-sided p values were reported, with statistical significance set at the 0.05 level. All analyses were conducted using SAS 9.4.

Results

Study population

Table 1 depicts sociodemographic, clinical, family history, and pathological characteristics of the 4091 patients eligible for analysis. Mean age at surgery was 64.1 (SD = 6.6) years and mean PSA at diagnosis was 7.0 (SD = 3.3) ng/ml. 25.3% reported a first-degree family history of PCa and 3.8% had a fatal family history of PCa. Overall, 63.7%, 15.4%, and 20.9% of patients had low risk, Gleason 6 FIR, and Gleason 3 + 4 FIR PCa, respectively. Of low-risk PCa patients, 7.2% and 12.0% were postoperatively upgraded and upstaged, respectively, and these numbers increased to 10.6% and 24.1% for Gleason 6 FIR PCa patients and 13.8% and 16.6% for Gleason 3 + 4 FIR PCa patients.

Predictors of upgrading and upstaging in men with low-risk PCa

On single logistic regression analysis, family history of PCa and other cancer as well as fatal family history were not associated with both upgrading and upstaging in low-risk PCa patients (Table 2). In the multiple analysis, higher
Table 1 Patient characteristics (n = 4091)

Preoperative risk stratification, n (%)  
- Low risk PCa 2607 (63.7)  
- Gleason 6 FIR PCa 630 (15.4)  
- Gleason 3 + 4 FIR PCa 854 (20.9)  

Upgrading* in low risk PCa patients, n (%)  
- Yes 183 (7.2)  
- No 2356 (92.8)  

Upgrading* in Gleason 6 FIR PCa patients, n (%)  
- Yes 67 (10.6)  
- No 563 (89.4)  

Upgrading* in Gleason 3 + 4 FIR PCa patients, n (%)  
- Yes 118 (13.8)  
- No 736 (86.2)  

Upstaging** in low risk PCa patients, n (%)  
- Yes 313 (12.0)  
- No 2294 (88.0)  

Upstaging** in Gleason 6 FIR PCa patients, n (%)  
- Yes 152 (24.1)  
- No 478 (75.9)  

Upstaging** in Gleason 3 + 4 FIR PCa patients, n (%)  
- Yes 142 (16.6)  
- No 712 (83.4)  

Age at surgery, mean (SD), years  
- ≤ 55, n (%) 389 (9.5)  
- > 55 to ≤ 65, n (%) 1741 (42.6)  
- > 65, n (%) 1961 (47.9)  

Family history of PCa, n (%)  
- Non 3934 (74.7)  
- First degree 748 (14.3)  
- Hereditary 286 (7.0)  

Fatal family history of PCa, n (%)  
- Non 3934 (96.2)  
- Yes 157 (3.8)  

Other cancer family history, n (%)  
- Non 2063 (50.4)  
- Yes 2027 (49.6)  

Secondary cancer, n (%)  
- Non 3565 (87.1)  
- Urologic 139 (3.4)  
- Non-urologic 387 (9.5)  

PSA at diagnosis, mean (SD), ng/mL  
- ≤ 4, n (%) 70 (3.3)  
- > 4 to ≤ 10, n (%) 475 (11.6)  
- > 10 to ≤ 20, n (%) 3010 (73.6)  
- > 20, n (%) 606 (14.8)  

DRE, n (%)  
- Non-suspicious 3218 (78.7)  
- Suspicious 873 (21.3)  

Pathological tumour stage, n (%)  
- ≤ pT2c 3509 (85.8)  
- pT3a 437 (10.7)  
- pT3b 124 (3.0)  

Table 1 (continued)

| Variable | n | (%) |
|----------|---|-----|
| pT4      | 21 | (0.5)  |

Pathological node stage, n (%)  
- pN0 4025 (98.5)  
- pN1 61 (1.5)  

Surgical margin, n (%)  
- R0 2651 (88.7)  
- R1 339 (11.3)  

Pathological Gleason Grade Group, n (%)  
- 1 2326 (58.6)  
- 2/3 120 (3.0)  
- 2 1205 (30.4)  
- 3 220 (5.5)  
- 4 97 (2.5)  

Adjuvant radiotherapy, n (%)  
- Yes 158 (3.9)  
- No 3933 (96.1)  

Adjuvant hormone therapy, n (%)  
- Yes 107 (2.6)  
- No 3984 (97.4)  

PCa prostate cancer, SD standard deviation, FIR favourable intermediate risk, PSA prostate-specific antigen, DRE digital rectal examination

*Upgrading was defined as postoperative Gleason Grade Group 3 tumour in radical prostatectomy  
**Upstaging was defined as pT3–pT4 or pN1 disease at radical prostatectomy

Predictors of upgrading and upstaging in men with FIR PCa

In single logistic regression analyses, neither family history nor fatal family history were associated with upgrading and upstaging in men with Gleason 6 FIR and Gleason 3 + 4 FIR PCa (Tables 3, 4). In multiple regression analyses, higher PSA at diagnosis (OR 1.14, 95% CI 1.05–1.23) was associated with postoperative upgrading. Secondary non-urologic cancers (OR 0.52, 95% CI 0.28–0.97) were associated with a lower risk of upgrading. Higher PSA at diagnosis (1.16, 95% CI 1.05–1.27) was associated with an increased risk of upstaging in Gleason 3 + 4 FIR PCa patients (Table 4).

Additionally, a separate regression analysis for upgrading and upstaging of the entire cohort was conducted to gain more statistical power. In this analysis, neither a positive family history nor a fatal family history of PCa were
Table 2  Single and multiple logistic regression analysis of upgrading and upstaging in men with low risk PCa

| Factors                                      | Upgrading                          |        |        |        |        |        |        |
|----------------------------------------------|------------------------------------|--------|--------|--------|--------|--------|--------|
|                                              | Single regression                  | OR     | 95% CI | p value| Multiple regressiona | OR     | 95% CI | p value|
| Age at surgery                               | <0.001                             | <0.001 |        | 0.083  |                     |        |        |        |
| Continuous                                   | 1.06 [1.03; 1.09]                  | 1.06 [1.03; 1.08] |        |        | 1.02 [1.00; 1.04] |        |        |        |
| Family history of PCa (ref: non)             | 0.893                              |        |        |        |                     |        |        |        |
| First degree                                 | 0.92 [0.62; 1.38]                  | 1.39 [1.04; 1.86] |        |        | 1.27 [0.84; 1.93] |        |        |        |
| Hereditary                                   | 0.91 [0.52; 1.61]                  |        |        |        |                     |        |        |        |
| Fatal family history of PCa (ref: non)       | 0.213                              | 1.57 [0.93; 2.64] |        |        | 0.092  |        |        |        |
| Yes                                          | 0.53 [0.19; 1.45]                  |        |        |        |                     |        |        |        |
| Other cancer family history (ref: non)       | 0.515                              |        |        |        |                     |        |        |        |
| Yes                                          | 1.11 [0.82; 1.49]                  | 0.97 [0.77; 1.23] |        |        | 0.824  |        |        |        |
| Secondary urologic cancer (ref: non)         | 0.225                              |        |        |        |                     |        |        |        |
| Urologic cancer                              | 0.49 [0.15; 1.56]                  | 1.25 [0.67; 2.33] |        |        | 0.486  |        |        |        |
| Secondary non-urologic cancer (ref: non)     | 0.061                              |        |        |        |                     |        |        |        |
| Non-urologic cancer                          | 0.55 [0.30; 1.03]                  | 1.01 [0.69; 1.50] |        |        | 0.951  |        |        |        |
| PSA at diagnosis (ng/ml)                     | <0.001                             | <0.001 |        | <0.001 |                     | <0.001 | <0.001 | <0.001 |
| Continuous                                   | 1.15 [1.07; 1.25]                  | 1.18 [1.11; 1.26] |        |        | 1.18    | [1.11; 1.26] |        |        |
| Suspicious                                   | 0.559                              | 0.81 [0.60; 1.10] |        |        | 0.175  |        |        |        |
| DRE (ref: non-suspicious)                    | 1.11 [0.78; 1.59]                  |        |        |        |                     |        |        |        |

OR: odds ratio, CI: confidence interval, PCa: prostate cancer, PSA: prostate-specific antigen, DRE: digital rectal examination

*aWith backward elimination (selection level 5%)*
associated with a higher likelihood of upgrading and upstaging, respectively (Supplementary Table 1). Furthermore, since upgrading from GGG 1 to GGG 2 is relevant concerning treatment decisions and patient counselling, we analysed additionally any upgrading from GGG 1 to GGG 2 in a separate regression analysis finding again no association between upgrading and a positive family history or a fatal family history in the multiple regression model (Supplementary Table 2).

Discussion

AS has been increasingly accepted as a safe approach to low-risk PCa with long-term outcomes similar to those of men with curative treatment strategies in randomized controlled trials [19] and in prospectively maintained cohorts [20, 21]. However, a major limitation is that a significant proportion of patients harbour occult higher-grade and higher-stage disease, which might lead to anxiety and refusal of AS initiation in at risk groups such as in men with a familial burden of PCa.

Results of this study showed that family history, defined as one or more first-degree relatives diagnosed with PCa including those with hereditary PCa, and fatal family history were not associated with postoperative upgrading or upstaging in men with low risk and FIR PCa. Since FIR patients represent a heterogeneous group [22], they were divided into Gleason 6 FIR and Gleason 3+4 FIR PCa patients for more specific association analysis. However, no detrimental effect of family history was observed. Therefore, FIR PCa patients with family history could be reassured that their familial burden of PCa is not associated with a higher rate of occult high-grade or high-stage disease compared to men with no family history and that AS might be a reasonable treatment option. Clearly, men with FIR disease should be informed of the risks of harbouring undetected higher-grade and higher-stage disease, since rates of postoperative upgrading and upstaging were higher in both Gleason 6 and Gleason 3+4 FIR patients compared to low-risk patients (upgrading: 13.8% and 10.6% vs. 7.2%; \( p < 0.001 \); upstaging: 24.1% and 16.6% vs. 12.0%; \( p < 0.001 \)), which could impact secondary therapies and increase risk of PCa progression. Reported rates of upgrading and upstaging are mostly consistent with results in the recent literature [12, 23–25]. Interestingly, a higher PSA level at diagnosis was a significant predictor of both upgrading and upstaging in low risk and FIR PCa, but not in Gleason 6 FIR PCa. The reasons remain unclear; however, the results indicate that the FIR PCa group is a heterogeneous group which warrants further investigation.

| Factors | Upgrading | Upstaging |
|---------|-----------|-----------|
|         | Single regression | Multiple regression | Single regression | Multiple regression |
|         | OR 95% CI | p value | OR 95% CI | p value | OR 95% CI | p value | OR 95% CI | p value |
| Age at surgery | | | | | | | |
| Continuous | 1.01 [0.97; 1.06] | 0.550 | 1.00 [0.97; 1.03] | 0.936 |
| Family history of PCa (ref: non) | | | | | | | |
| First degree | 0.45 [0.19; 1.07] | 0.194 | 0.56 [0.32; 0.98] | 0.117 |
| Hereditary | 1.03 [0.35; 3.04] | 0.056 | 1.09 [0.49; 2.41] | 0.014 |
| Fatal family history of PCa (ref: non) | | | | | | | |
| Yes | 0.810 | 0.810 | 0.52 [0.15; 1.77] | 0.292 |
| Other cancer family history (ref: non) | | | | | | | |
| Yes | 1.33 [0.80; 2.21] | 0.281 | 1.38 [0.96; 2.00] | 0.083 |
| Secondary urologic cancer (ref: non) | | | | | | | |
| Urologic cancer | 1.21 [0.35; 4.17] | 0.769 | 1.39 [0.56; 3.46] | 0.473 |
| Secondary non-urologic cancer | | | | | | | |
| Non-urologic cancer | 1.63 [0.73; 3.64] | 0.233 | 1.05 [0.55; 2.03] | 0.876 |
| PSA at diagnosis (ng/ml) | | | | | | | |
| Continuous | 1.05 [0.96; 1.16] | 0.283 | 1.00 [0.94; 1.08] | 0.943 |
| DRE (ref: non-suspicious) | | | | | | | |
| Suspicious | 1.10 [0.63; 1.94] | 0.733 | 0.77 [0.50; 1.19] | 0.238 |

OR: odds ratio, CI: confidence interval, PCa: prostate cancer, PSA: prostate-specific antigen, DRE: digital rectal examination

*With backward elimination (selection level 5%)
Table 4  Single and multiple logistic regression analysis of upgrading and upstaging in men with Gleason 3+4 favourable intermediate risk PCa

| Factors                                      | Upgrading | Upstaging |
|----------------------------------------------|-----------|-----------|
|                                              | Single regression | Multiple regression | Single regression | Multiple regression |
|                                              | OR 95% CI  | p value   | OR 95% CI  | p value   | OR 95% CI  | p value   | OR 95% CI  | p value   |
| Age at surgery                               | 0.052     | 0.029     | 1.03 [1.00; 1.06] | 0.021     | 1.03 [1.01; 1.06] | 0.022     |
| Continuous                                   | 1.03 [1.00; 1.06] | 0.029     | 1.03 [1.01; 1.06] | 0.021     | 1.03 [1.01; 1.06] | 0.022     |
| Family history of PCa (ref: non)             | 0.450     | 0.221     | 1.04 [0.67; 1.61] | 0.525     | 0.52 [0.18; 1.48] | 0.525     |
| First degree                                 | 0.73 [0.44; 1.22] | 0.525     | 1.04 [0.67; 1.61] | 0.525     | 0.52 [0.18; 1.48] | 0.525     |
| Hereditary                                    | 0.78 [0.30; 2.02] | 0.525     | 0.52 [0.18; 1.48] | 0.525     | 0.52 [0.18; 1.48] | 0.525     |
| Fatal family history of PCa (ref: non)       | 0.233     | 0.525     | 0.71 [0.25; 2.05] | 0.525     | 0.71 [0.25; 2.05] | 0.525     |
| Yes                                          | 0.42 [0.10; 1.76] | 0.525     | 0.71 [0.25; 2.05] | 0.525     | 0.71 [0.25; 2.05] | 0.525     |
| Other cancer family history (ref: non)       | 0.729     | 0.953     | 1.01 [0.70; 1.45] | 0.953     | 1.01 [0.70; 1.45] | 0.953     |
| Yes                                          | 0.93 [0.63; 1.38] | 0.953     | 1.01 [0.70; 1.45] | 0.953     | 1.01 [0.70; 1.45] | 0.953     |
| Secondary urologic cancer (ref: non)         | 0.783     | 0.064     | 0.15 [0.02; 1.11] | 0.064     | 0.15 [0.02; 1.11] | 0.064     |
| Urologic cancer                              | 1.15 [0.43; 3.04] | 0.064     | 0.15 [0.02; 1.11] | 0.064     | 0.15 [0.02; 1.11] | 0.064     |
| Secondary non-urologic cancer (ref: non)     | 0.698     | 0.948     | 0.70 [0.41; 1.20] | 0.948     | 0.70 [0.41; 1.20] | 0.948     |
| Non-urologic cancer                          | 1.14 [0.58; 2.24] | 0.948     | 0.70 [0.41; 1.20] | 0.948     | 0.70 [0.41; 1.20] | 0.948     |
| PSA at diagnosis (ng/ml)                     | 0.013     | 0.003     | 1.16 [1.05; 1.27] | 0.003     | 1.16 [1.05; 1.27] | 0.003     |
| Continuous                                   | 1.14 [1.03; 1.27] | 0.003     | 1.16 [1.05; 1.27] | 0.003     | 1.16 [1.05; 1.27] | 0.003     |
| DRE (ref: non-suspicious)                    | 0.023     | 0.192     | 1.73 [1.08; 2.76] | 0.192     | 1.73 [1.08; 2.76] | 0.192     |
| Suspicious                                   | 1.73 [1.08; 2.76] | 0.192     | 1.73 [1.08; 2.76] | 0.192     | 1.73 [1.08; 2.76] | 0.192     |

OR: odds ratio, CI: confidence interval, PCa: prostate cancer, PSA: prostate-specific antigen, DRE: digital rectal examination

*With backward elimination (selection level 5%)
In line with previous findings [26], this study found an association between a suspicious DRE and a higher risk of postoperative upgrading in Gleason 3 + 4 FIR PCa patients, which emphasises the important role of DRE despite recent controversy over the usefulness in PCa staging. Indeed, emerging evidence suggests that sensitivity, specificity, negative and positive predictive values of DRE to detect clinically significant PCa were better when PSA levels were lower [27]. This result is consistent with findings here since PSA levels of the Gleason 3 + 4 FIR group were lower compared to the Gleason 6 FIR group (6.1 ng/ml vs. 13.0 ng/ml; \( p < 0.001 \); data not shown).

In the present analysis, older age was only associated with a higher risk of upgrading among low-risk PCa patients. Contradictory results have been likewise reported in the literature [24, 26, 28, 29]. Nevertheless, this factor merits further investigation to avoid overtreatment in elderly patients who have a higher risk of death from competing causes when treated with definitive curative treatment [30].

The strength of this study is the large nationwide, population-based sample with verified, complete, and detailed information concerning family history and fatal family history of PCa. Limitations include first that mpMRI and targeted fusion biopsies were rarely used during the study period and hence were excluded from the analysis. Second, patients were selected for RP and hence may not be representative of all PCa patients as a result of selection bias. Third, information on prognostic factors of unfavourable outcomes, such as perineural invasion, percentage PCa in a core, and PSA density were lacking and not incorporated in the analysis. Furthermore, biopsies were neither performed according to a uniform protocol for biopsy core collection nor centrally reviewed. Additionally, biopsy and prostatectomy specimen were not consistently reviewed centrally by the same uropathologist, increasing the risk of inter-observer variation of grading. Finally, the study was retrospective and subject to the usual limitations of retrospective analyses.

Conclusions

Results of the present study showed no detrimental effect of family history on postoperative upgrading or upstaging in men with low risk and FIR PCa. Patients with a fatal family history of PCa had likewise no increased risk of postoperative upgrading or upstaging. Separate evaluation in Gleason 6 FIR and Gleason 3 + 4 FIR PCa patients confirmed the conclusions. Family history or fatal family history in FIR PCa patients should not be a reason to refrain from AS that is otherwise suitable.

Author contributions KH: protocol development, data collection, data management, manuscript editing. NM: data collection and data management, manuscript editing. DPA: data analysis, and manuscript writing and editing. SS: data management, data analysis, and manuscript editing. JEG: protocol and project development, manuscript editing. VHM: protocol and project development, data management, manuscript writing and editing.

Funding Open Access funding enabled and organized by Projekt DEAL. There was no funding provided for this study.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Research involving human participants and/or animals Anonymous data of human participants were involved in this study. Animals were not included in this study.

Informed consent Informed consent was obtained from all individual participants included in the study.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Mohler JL, Armstrong AJ, Bahnson RR et al (2016) Prostate cancer, Version 1.2016. J Natl Compr Canc Netw 14(1):19–30. https://doi.org/10.6004/jnccn.2016.0004
2. Ploussard G, Isbarn H, Briganti A et al (2015) Can we expand active surveillance criteria to include biopsy Gleason 3+4 prostate cancer? A multi-institutional study of 2323 patients. Urol Oncol 33(2):71.e71-79. https://doi.org/10.1016/j.urolonc.2014.07.007
3. Yamamoto T, Musunuru HB, Vesprini D et al (2016) Metastatic prostate cancer in men initially treated with active surveillance. J Urol 195(5):1409–1414. https://doi.org/10.1016/j.juro.2015.11.075
4. Raldow AC, Zhang D, Chen MH, Braccioforte MH, Moran BJ, D’Amico AV (2015) Risk Group and Death From Prostate Cancer: Implications for Active Surveillance in Men With Favorable Intermediate-Risk Prostate Cancer. JAMA Oncol 1(3):334–340. https://doi.org/10.1001/jamaoncol.2014.284
5. Corcoran NM, Hovens CM, Hong MK et al (2012) Underestimation of Gleason score at prostate biopsy reflects sampling error in lower volume tumours. BJU Int 109(5):660–664. https://doi.org/10.1111/j.1464-410X.2011.10543.x
6. Morlacco A, Cheville JC, Rangel LJ, Gearman DJ, Karnes RJ (2017) Adverse disease features in Gleason Score 3 + 4 “favorable intermediate-risk” prostate cancer: implications for active
7. Kaye DR, Qi J, Morgan TM et al (2019) Pathological upgrading at radical prostatectomy for patients with Grade Group 1 prostate cancer: implications of confirmatory testing for patients considering active surveillance. BJU Int 123(5):846–853. https://doi.org/10.1111/bju.14554

8. Ploussard G, Beauval JB, Lesourd M et al (2020) Performance of systematic, MRI-targeted biopsies alone or in combination for the prediction of unfavourable disease in MRI-positive low-risk prostate cancer patients eligible for active surveillance. World J Urol 38(3):663–671. https://doi.org/10.1007/s00345-019-02848-x

9. Mamawala MK, Meyer AR, Landis PK et al (2020) Utility of multiparametric magnetic resonance imaging in the risk stratification of men with Grade Group 1 prostate cancer on active surveillance. BJU Int 125(6):861–866. https://doi.org/10.1111/bju.15033

10. Björnebo L, Olsson H, Nordström T et al (2020) Predictors of adverse pathology on radical prostatectomy specimen in men initially enrolled in active surveillance for low-risk prostate cancer. World J Urol. https://doi.org/10.1007/s00345-020-03394-7

11. Maurice MJ, Sundi D, Schaeffer EM, Abouassaly R (2017) Risk of pathological upgrading and upstaging among men with low risk prostate cancer varies by race: results from the National Cancer Database. J Urol 197(3 Pt 1):627–631. https://doi.org/10.1016/j.juro.2016.08.095

12. Dinh KT, Mahal BA, Ziehr DR et al (2015) Incidence and predictors of upgrading and upstaging among 10,000 contemporary patients with low risk prostate cancer. J Urol 194(2):343–349. https://doi.org/10.1016/j.juro.2015.02.015

13. Jansson F, Folkvaljon F, Stattin P, Bratt O, Akre O (2020) Risk of postoperative upstaging or upgrading among men with low risk familial prostate cancer. J Urol 204(1):79–81. https://doi.org/10.1097/rua.0000000000000793

14. Meissner VH, Strüh JGH, Kron M et al (2020) The role of fatal family history and mode of inheritance in prostate cancer for long-term outcomes following radical prostatectomy. World J Urol. https://doi.org/10.1007/s00345-020-03147-6

15. Paiss T, Herkommer K, Chab A et al (2002) Familial prostate carcinoma in Germany. Urologe A 41(1):38–43. https://doi.org/10.1007/s120-002-8229-2

16. Sandra MG, Cadedu JA, Kirkby E et al (2018) Clinically localized prostate cancer: AUA/ASTRO/SUO Guideline. Part I: risk stratification, shared decision making, and care options. J Urol 199(5):683–690. https://doi.org/10.1016/j.juro.2017.11.095

17. Epstein JI, Zelefsky MJ, Stjoberg DD et al (2016) A contemporary prostate cancer grading system: a validated alternative to the Gleason Score. Eur Urol 69(3):428–435. https://doi.org/10.1016/j.euro.2015.06.046

18. Carter BS, Bova GS, Beaty TH et al (1993) Hereditary prostate cancer: epidemiologic and clinical features. J Urol 150(3):797–802. https://doi.org/10.1016/s0022-5347(17)35617-3

19. Hamdy FC, Donovan JL, Lane JA et al (2016) 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 375(15):1415–1424. https://doi.org/10.1056/NEJMo1606220

20. Klotz L, Vesprini D, Sethukavalan P et al (2015) Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol 33(3):272–277. https://doi.org/10.1200/jco.2014.55.1192

21. Tosoian JJ, Mamawala M, Epstein JI et al (2015) Intermediate and longer-term outcomes from a prospective active-surveillance program for favorable-risk prostate cancer. J Clin Oncol 33(30):3379–3385. https://doi.org/10.1200/jco.2015.62.5764

22. Beauval JB, Ploussard G, Cabarrou B et al (2017) Improved decision making in intermediate-risk prostate cancer: a multicenter study on pathologic and oncologic outcomes after radical prostatectomy. World J Urol 35(8):1191–1197. https://doi.org/10.1007/s00345-016-1979-z

23. Patel HD, Gupta M, Tosoian JJ, Carter HB, Partin AW, Epstein JI (2018) Subtyping the risk of intermediate risk prostate cancer for active surveillance based on adverse pathology at radical prostatectomy. J Urol 200(5):1068–1074. https://doi.org/10.1016/j.juro.2018.04.058

24. Yang DD, Mahal BA, Muralidhar V et al (2019) Risk of upgrading and upstaging among 10,000 patients with Gleason 3+4 favorable intermediate-risk prostate cancer. Eur Urol Focus 5(1):69–76. https://doi.org/10.1016/j.euf.2017.05.011

25. Gearman VH, Torlasco C, Cheville JC, Rangel LJ, Karnes RJ (2018) Comparison of pathological and oncologic outcomes of favorable risk Gleason Score 3 + 4 and low risk Gleason Score 6 prostate cancer: considerations for active surveillance. J Urol 199(5):1188–1195. https://doi.org/10.1016/j.juro.2017.11.116

26. Vellekoop A, Loeb S, Folkvaljon Y, Stattin P (2014) Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer. J Urol 191(2):350–357. https://doi.org/10.1016/j.juro.2013.09.034

27. Herrera-Caceres JO, Wettstein MS, Goldberg H et al (2020) Utility of digital rectal examination in a population with prostate cancer treated with active surveillance. Can Urol Assoc J. https://doi.org/10.5489/cuaj.6341

28. De Nunzio C, Brassetti A, Simone G et al (2018) Metabolic syndrome increases the risk of upgrading and upstaging in patients with prostate cancer on biopsy: a radical prostatectomy multicenter cohort study. Prostate Cancer Prostatic Dis 21(3):438–445. https://doi.org/10.1038/s41391-018-0054-9

29. Herlemann A, Bucner A, Kretschmer A, Apfelbeck M, Stief CG, Gratzeck C, Tritschler S (2017) Postoperative upgrading of prostate cancer in men ≥ 75 years: a propensity score-matched analysis. World J Urol 35(10):1517–1524. https://doi.org/10.1007/s00345-017-2045-1

30. Daskivich TJ, Champi K, Kwan L et al (2011) Comorbidity and competing risks for mortality in men with prostate cancer. Cancer 117(20):4642–4650. https://doi.org/10.1002/cncr.26104

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.